NDC 70709-013
SAJAZIR
Icatibant
SAJAZIR is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Cycle Pharmaceuticals Ltd-uk. The primary component is Icatibant Acetate.
| Product ID | 70709-013_329a6e8e-da19-491a-acbc-3afd6e40bc1c |
| NDC | 70709-013 |
| Product Type | Human Prescription Drug |
| Proprietary Name | SAJAZIR |
| Generic Name | Icatibant |
| Dosage Form | Injection |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2021-06-03 |
| Marketing Category | ANDA / |
| Application Number | ANDA212446 |
| Labeler Name | Cycle Pharmaceuticals Ltd-Uk |
| Substance Name | ICATIBANT ACETATE |
| Active Ingredient Strength | 30 mg/3mL |
| Pharm Classes | Bradykinin B2 Receptor Antagonist [EPC], Bradykinin B2 Receptor Antagonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 70709-013-01
1 SYRINGE, GLASS in 1 CARTON (70709-013-01) > 3 mL in 1 SYRINGE, GLASS
| Marketing Start Date | 2021-06-03 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
NDC Crossover Matching brand name "SAJAZIR" or generic name "Icatibant"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 70709-013 | SAJAZIR | ICATIBANT |
| 0093-3066 | Icatibant | Icatibant |
| 24201-207 | Icatibant | icatibant |
| 54092-135 | Icatibant | Icatibant |
| 63323-574 | Icatibant | Icatibant |
| 69097-664 | ICATIBANT | ICATIBANT |
| 71225-114 | Icatibant | Icatibant |
Trademark Results [SAJAZIR]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 SAJAZIR 90461564 not registered Live/Pending |
Cycle Pharmaceuticals Ltd. 2021-01-12 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.